Company Overview
About Nuvig Therapeutics
Nuvig Therapeutics is a privately held biotechnology company developing next-generation immunomodulatory therapies for patients with chronic inflammatory and autoimmune diseases. Its lead candidate, NVG-2089, is a first-in-class recombinant Fc fragment engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that restores immune balance without the broad immunosuppression associated with existing treatments.
Business Model & Competitive Advantage
In December 2024, Nuvig announced a $161 million Series B financing co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners, with participation from B Capital, Leaps by Bayer, Bristol Myers Squibb, Novo Holdings, and others. This followed a $47 million Series A led by Novo Holdings in May 2022. NVG-2089 is advancing into Phase 2 clinical development for chronic inflammatory demyelinating polyneuropathy (CIDP) and additional undisclosed autoimmune indications.
Competitive Landscape 2025–2026
Nuvig''s platform aims to preserve normal immune function while achieving durable disease control — a key differentiation from corticosteroids, IVIg, and other broad immunosuppressants used in current autoimmune treatment protocols.
Key Differentiators
Strong Challenger
Nuvig Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Nuvig Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nuvig Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nuvig Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nuvig Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →